Payment overview · 2025
General Payments
$934.45
55 reported records · 15 companies
Healthcare provider profile · identity verified
Daniel Trevor Young, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · DRAPER, UT · NPI 1114301710
Verified facts
What the public records show
CMS Open Payments records show Daniel Trevor Young, D.O. received $934.45 in general payments during 2025 across 55 reported records.
ABBVIE INC. accounted for 21.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 215 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 230 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 215 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Paxlovid by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Soliqua 100-33 by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $204.39 | 21.9% | 13 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $189.61 | 20.3% | 9 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $144.32 | 15.4% | 11 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $67.19 | 7.2% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $53.96 | 5.8% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $52.71 | 5.6% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $46.77 | 5.0% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $36.41 | 3.9% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $32.91 | 3.5% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $22.77 | 2.4% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $20.83 | 2.2% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $17.08 | 1.8% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$16.23 | 1.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.99 | 1.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $14.28 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $934.45 | 55 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $189.61 | 9 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $118.42 | 7 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $116.06 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $85.97 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $85.97 | 6 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $53.96 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $48.71 | 3 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $47.44 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $46.77 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $37.26 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $36.41 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $32.91 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $22.77 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $20.83 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.81 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.48 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $18.08 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $17.08 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $16.23 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.99 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $14.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 215 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 67 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 230 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
39 | 12 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
52 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
46 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
215 | 60 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
67 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
69 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
61 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
230 | 57 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
215 | 60 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
20 | 20 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 701 | 215 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 686 | 210 |
| Levothyroxine Sodium | Levothyroxine Sodium | 633 | 200 |
| Losartan Potassium | Losartan Potassium | 560 | 172 |
| Omeprazole | Omeprazole | 439 | 140 |
| Amlodipine Besylate | Amlodipine Besylate | 435 | 144 |
| Metformin Hcl Er | Metformin Hcl | 333 | 108 |
| Tamsulosin Hcl | Tamsulosin Hcl | 331 | 109 |
| Gabapentin | Gabapentin | 305 | 120 |
| Simvastatin | Simvastatin | 281 | 89 |
| Ozempic | Semaglutide | 230 | 57 |
| Trazodone Hcl | Trazodone Hcl | 229 | 76 |
| Lisinopril | Lisinopril | 224 | 73 |
| Metformin Hcl | Metformin Hcl | 223 | 77 |
| Zolpidem Tartrate | Zolpidem Tartrate | 216 | 75 |
| Eliquis | Apixaban | 215 | 60 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 199 | 58 |
| Potassium Chloride | Potassium Chloride | 193 | 67 |
| Hydrochlorothiazide | Hydrochlorothiazide | 180 | 57 |
| Spironolactone | Spironolactone | 164 | 53 |
| Alendronate Sodium | Alendronate Sodium | 158 | 48 |
| Allopurinol | Allopurinol | 158 | 47 |
| Montelukast Sodium | Montelukast Sodium | 155 | 53 |
| Pantoprazole Sodium | Pantoprazole Sodium | 154 | 56 |
| Duloxetine Hcl | Duloxetine Hcl | 146 | 43 |
| Finasteride | Finasteride | 140 | 40 |
| Sertraline Hcl | Sertraline Hcl | 134 | 49 |
| Tramadol Hcl | Tramadol Hcl | 129 | 41 |
| Carvedilol | Carvedilol | 119 | 45 |
| Escitalopram Oxalate | Escitalopram Oxalate | 113 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 111 | 42 |
| Famotidine | Famotidine | 109 | 39 |
| Fluoxetine Hcl | Fluoxetine Hcl | 105 | 30 |
| Quetiapine Fumarate | Quetiapine Fumarate | 101 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 99 | 47 |
| Ezetimibe | Ezetimibe | 94 | 34 |
| Lorazepam | Lorazepam | 93 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 90 | 32 |
| Furosemide | Furosemide | 89 | 40 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 88 | 27 |
| Alprazolam | Alprazolam | 85 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 81 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 76 | 26 |
| Pregabalin | Pregabalin | 71 | 20 |
| Mounjaro | Tirzepatide | 69 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 68 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 67 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 67 | 19 |
| Jardiance | Empagliflozin | 67 | 25 |
| Glimepiride | Glimepiride | 66 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 65 | 22 |
| Tresiba Flextouch U-200 | Insulin Degludec | 65 | 16 |
| Celecoxib | Celecoxib | 62 | 25 |
| Donepezil Hcl | Donepezil Hcl | 62 | 24 |
| Trulicity | Dulaglutide | 61 | 13 |
| Fenofibrate | Fenofibrate | 60 | 19 |
| Meloxicam | Meloxicam | 60 | 27 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 58 | 32 |
| Ipratropium Bromide | Ipratropium Bromide | 57 | 26 |
| Bupropion Xl | Bupropion Hcl | 56 | 22 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 55 | 43 |
| Prednisone | Prednisone | 54 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 53 | 22 |
| Myrbetriq | Mirabegron | 52 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 52 | 18 |
| Azithromycin | Azithromycin | 48 | 41 |
| Chlorthalidone | Chlorthalidone | 48 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 48 | 31 |
| Raloxifene Hcl | Raloxifene Hcl | 48 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 48 | 16 |
| Memantine Hcl | Memantine Hcl | 47 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 47 | 12 |
| Farxiga | Dapagliflozin Propanediol | 46 | 13 |
| Buspirone Hcl | Buspirone Hcl | 41 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 41 | 35 |
| Ondansetron Hcl | Ondansetron Hcl | 40 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 40 | 15 |
| Valacyclovir | Valacyclovir Hcl | 40 | 24 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 39 | 13 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 39 | 19 |
| Synthroid | Levothyroxine Sodium | 39 | 12 |
| Telmisartan | Telmisartan | 39 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 32 |
| Atenolol | Atenolol | 37 | 12 |
| Propranolol Hcl | Propranolol Hcl | 37 | 14 |
| Xarelto | Rivaroxaban | 37 | 12 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | 12 |
| Estradiol | Estradiol | 35 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 35 | 11 |
| Fluconazole | Fluconazole | 34 | 25 |
| Ibuprofen | Ibuprofen | 34 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 33 | 27 |
| Mirtazapine | Mirtazapine | 32 | suppressed |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 29 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 29 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 29 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Ondansetron Odt | Ondansetron | 28 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 28 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 27 | suppressed |
| Nystatin | Nystatin | 27 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 27 | suppressed |
| Glipizide | Glipizide | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 25 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 25 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 25 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 25 | 11 |
| Cefdinir | Cefdinir | 24 | 22 |
| Irbesartan | Irbesartan | 24 | suppressed |
| Acyclovir | Acyclovir | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 23 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Cephalexin | Cephalexin | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 16 | suppressed |
| Testosterone | Testosterone | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 15 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Clonazepam | Clonazepam | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 12 |
| Naproxen | Naproxen | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Repatha Syringe | Evolocumab | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Avalide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $934.45 · 55 records | ABBVIE INC. | AREXVY, BREZTRI, CAMZYOS, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FREESTYLE LIBRE 3, JARDIANCE, MINIMED 780G, NURTEC ODT, Ozempic, QULIPTA, REXULTI, Rybelsus, TRELEGY ELLIPTA, TRINTELLIX, TZIELD, UBRELVY, VRAYLAR, Veozah, ZAVZPRET | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error